REVIEW ON PHYTOCHEMICALS AS ANTI-AMYLOID AGENTS IN PARKINSON DISEASE

Jayshri Swarnkar
Faculty of Pharmacy, Kalinga University, Naya Raipur
Email: Jayshri.swarnkar@kalingauniversity.ac.in

Abstract:

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons and the accumulation of misfolded protein aggregates, including amyloid-beta and alpha-synuclein, in the brain. The search for effective therapeutic strategies to target amyloid aggregation in PD has led to increasing interest in natural compounds, particularly phytochemicals, due to their potential as anti-amyloid agents. This review article provides a comprehensive overview of the current knowledge on phytochemicals as potential therapeutic agents for targeting amyloid aggregation in PD. We summarize the evidence from in vitro and in vivo studies that highlight the anti-amyloid properties of various phytochemicals, including curcumin, resveratrol, epigallocatechin gallate (EGCG), quercetin, and others. We discuss the mechanisms through which these phytochemicals modulate amyloid formation, inhibit aggregation, and promote amyloid clearance. Furthermore, we explore their potential neuroprotective effects, including antioxidant, anti-inflammatory, and anti-apoptotic activities. Additionally, we examine the challenges associated with the development of phytochemical-based therapies, such as bioavailability and pharmacokinetics, and the need for further preclinical and clinical studies. Overall, this review underscores the promising potential of phytochemicals as anti-amyloid agents in PD and highlights the need for continued research to fully understand their mechanisms of action, optimize their therapeutic properties, and facilitate their translation into clinical practice for the benefit of PD patients.

Keywords: Parkinson Disease, Neurodegenerative disease, resveratrol, Amyloid aggregation, alpha-synuclein

Introduction:

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra, a region of the brain responsible for motor control. It is the second most common neurodegenerative disorder after Alzheimer's disease, affecting millions of people worldwide. The cardinal symptoms of PD include bradykinesia (slowness of movement), rigidity, resting tremor, and postural instability. However, the disease is not limited to motor symptoms; non-motor symptoms such as cognitive impairment, sleep disturbances, and autonomic dysfunction also occur. [1]

The pathological hallmark of PD is the presence of Lewy bodies, which are abnormal protein aggregates primarily composed of α-synuclein, within neurons. These aggregates disrupt

cellular function and lead to the degeneration and death of dopaminergic neurons in the substantia nigra. Accumulating evidence suggests that the aggregation and accumulation of α-synuclein, along with impaired protein clearance mechanisms, contribute to the development and progression of PD. [2]

Amyloid aggregation, a process characterized by the misfolding and self-assembly of proteins into insoluble fibrillary structures, has long been associated with neurodegenerative diseases. In PD, the aggregation of α-synuclein into toxic oligomers and fibrils is considered a key pathological event. These aggregates can propagate throughout the brain, promoting neurotoxicity and neuronal dysfunction. [3] Given the central role of α-synuclein aggregation in PD pathogenesis, there is growing interest in developing therapeutic strategies to target and prevent amyloid formation. Phytochemicals, bioactive compounds derived from plants, have emerged as potential anti-amyloid agents in PD. These natural compounds possess diverse chemical structures and exhibit various biological activities, including antioxidant, anti-inflammatory, and neuroprotective effects.

Understanding the potential of phytochemicals as anti-amyloid agents in PD is crucial for developing novel therapeutic approaches. By targeting the mechanisms underlying α-synuclein aggregation, these compounds have the potential to modulate disease progression and ameliorate motor and non-motor symptoms. [4] This review aims to comprehensively evaluate the current knowledge regarding phytochemicals as anti-amyloid agents in PD, focusing on their mechanisms of action, preclinical and clinical evidence, and future directions for research. By exploring the therapeutic potential of phytochemicals, we may pave the way for the development of innovative treatments that can ultimately improve the lives of individuals living with PD.

Occurrence and Prevalence of disease

The prevalence of Parkinson disease increases with age, making it more common in the elderly population. In terms of global occurrence, it is estimated that around 6.1 million individuals worldwide had Parkinson's disease in 2016. However, it's important to note that the actual numbers may be higher due to under-diagnosis and limited access to healthcare in certain regions. [5] There can be regional differences in the prevalence of PD, with studies suggesting higher rates in developed countries compared to developing nations. This discrepancy may be influenced by various factors, including differences in healthcare infrastructure, genetic susceptibility, environmental factors, and data collection methods.

While Parkinson's disease can affect both men and women, some studies indicate a slightly higher prevalence in men. The reasons for this gender difference are not yet fully understood and require further investigation. Parkinson's disease is more commonly diagnosed in older adults, particularly those over the age of 60. [6] The prevalence of PD increases with age, and it is estimated that around 1% to 2% of individuals aged 65 and older have the disease. However, cases of early-onset Parkinson's can also occur, typically before the age of 50, although they are relatively less common.

The prevalence of Parkinson's disease can vary across different regions. Some studies have indicated that PD is more common in developed countries compared to developing nations, possibly due to differences in healthcare access, environmental factors, or genetic

predisposition. [7] However, the exact prevalence rates may vary across studies and populations. Parkinson's disease appears to affect both males and females, but some studies suggest a slightly higher prevalence in men. The reasons behind this gender difference are not yet fully understood and require further research.

Neuropathological Insights into Parkinson's disease

The primary pathological hallmark of PD is the loss of dopaminergic neurons in a brain region called the substantia nigra pars compacta. This neuronal loss is accompanied by the formation of intracellular protein aggregates known as Lewy bodies. These Lewy bodies are primarily composed of an abnormal accumulation of a protein called α-synuclein. [8] The aggregation of α-synuclein disrupts cellular function and leads to the degeneration and death of dopaminergic neurons. In addition to the substantia nigra, α-synuclein aggregates can also be found in other regions of the brain, including the cortex, hippocampus, and olfactory bulb. The widespread distribution of these aggregates contributes to the involvement of non-motor symptoms in PD, such as cognitive impairment, olfactory dysfunction, and autonomic disturbances. [9]

The progressive degeneration of dopaminergic neurons in the substantia nigra results in a deficiency of dopamine, a neurotransmitter essential for motor control. This dopamine deficiency leads to the characteristic motor symptoms of PD, including bradykinesia (slowness of movement), rigidity, resting tremor, and postural instability. These motor symptoms typically manifest asymmetrically, affecting one side of the body initially before spreading to both sides as the disease progresses. [10]

Apart from the loss of dopaminergic neurons and α-synuclein pathology, other pathological features in PD include neuro-inflammation, oxidative stress, mitochondrial dysfunction, and impaired protein clearance mechanisms. These processes contribute to neuronal damage and further progression of the disease.

Understanding the pathological features of PD is crucial for developing therapeutic strategies that target the underlying mechanisms and provide symptomatic relief. Ongoing research aims to elucidate the complex interplay between these pathological processes, identify potential biomarkers for early diagnosis, and develop disease-modifying treatments to slow or halt the progression of Parkinson's disease. [11]

Role of Amyloid aggregation in progression of Parkinson disease:

Amyloid-(A) plaque deposition is thought to be the primary symptom of Parkinson Disease (AD). It was first purified in 1984, which is when a discovery was made. The microtubule-associated protein Tau and its phosphorylated version P-Tau are also thought to contribute to AD along with A. More than 80% of PD patients who live for more than 10 years will eventually develop dementia, with a reported average point prevalence of 40%, although the time to develop dementia varies from a few years to many years and even decades after. [12] Cognitive deficits in PD are now known to occur in the prodromal and de novo state. Because of this phenomena, researchers are now more interested in whether PD dementia (PDD), which is known to be caused by brain A deposition and -synuclein, and AD may share certain pathophysiological mechanisms. A rapid deterioration in cognitive function and a shorter lifespan have been linked to the subset of AD patients with A and Lewy body deposits (in

about>50% of AD cases). This observation is supported by the discovery of Amyloid plaques along the normal Lewy body deposition in patients with Lewy body spectrum diseases, primarily dementia with Lewy bodies (DLB) and, to a lesser extent, PDD patients. [13]

α-Synuclein is a naturally occurring protein found abundantly in the brain, primarily in presynaptic terminals. However, in PD, α-synuclein undergoes misfolding and aggregation, leading to the formation of insoluble clumps known as Lewy bodies and Lewy neurites. The aggregation of α-synuclein is believed to play a central role in the neurodegenerative processes underlying PD. It is thought that the accumulation of these aggregates contributes to the progressive loss of dopaminergic neurons in the substantia nigra region of the brain, which is responsible for producing dopamine, a neurotransmitter involved in motor control. [14]

Additionally, Aβ has been implicated in the formation of Lewy bodies, which are abnormal protein aggregates primarily composed of alpha-synuclein, another protein associated with PD. Lewy bodies are a hallmark pathological feature of PD. It is hypothesized that Aβ may promote the aggregation of alpha-synuclein, leading to the formation of Lewy bodies and the subsequent neurodegeneration observed in PD. Furthermore, studies have suggested that Aβ may interact with other molecular pathways involved in PD, such as oxidative stress, mitochondrial dysfunction, and inflammation. These interactions could potentially exacerbate neurodegeneration and contribute to disease progression. [15]

Numerous research studies have provided valuable insights into the role of α-synuclein aggregation in the progression of Parkinson's disease (PD). α-synuclein is a key player in the pathology of PD, and its aggregation has been strongly linked to the neurodegenerative processes underlying the disease.

Studies have shown that the accumulation of aggregated α-synuclein in the form of Lewy bodies and Lewy neurites correlates with the severity of motor symptoms in PD patients. This suggests a direct association between α-synuclein aggregation and disease progression. Experimental models have further supported this correlation by demonstrating that the presence of α-synuclein aggregates in the brain is sufficient to induce neurodegeneration and motor impairments. [16]

The spread of α-synuclein pathology throughout the brain is another crucial aspect of PD progression. Emerging evidence suggests that misfolded α-synuclein can propagate from neuron to neuron, leading to the progressive spread of pathology. This prion-like behavior is hypothesized to contribute to the characteristic pattern of neurodegeneration observed in PD, starting from the substantia nigra and spreading to other brain regions involved in motor control and cognitive function. [17]

Furthermore, studies have highlighted the toxic effects of aggregated α-synuclein on cellular processes. It has been observed that these aggregates disrupt protein homeostasis, impair mitochondrial function, and generate oxidative stress, ultimately leading to neuronal dysfunction and degeneration. The formation of α-synuclein aggregates also interferes with intracellular transport mechanisms, affecting the proper distribution of essential cellular components and contributing to neuronal damage. [18]

The immune response and neuroinflammation triggered by α-synuclein aggregation play a significant role in PD progression. Studies have demonstrated the activation of microglia, the brain's immune cells, in response to aggregated α-synuclein. This immune response leads to the release of pro-inflammatory cytokines and reactive oxygen species, exacerbating neurodegeneration and promoting neuronal death. [19]

However, it is important to note that the role of Aβ in PD is still a topic of active research, and its exact contribution to the disease process remains unclear. Parkinson's disease is a complex disorder with multiple pathological mechanisms, and the involvement of Aβ is likely to be influenced by various factors, including genetic predisposition and other comorbidities. Overall, while there is evidence suggesting a potential role for Aβ in the progression of PD, further research is needed to fully understand its contribution and to determine whether targeting Aβ could be a viable therapeutic strategy for PD patients.[20]

Role of phytochemical as potential treatment of Parkinson disease.

Phytochemicals, natural compounds found in plants, have emerged as promising candidates for the treatment of Parkinson's disease (PD). These compounds offer various benefits due to their antioxidant, anti-inflammatory, and neuroprotective properties. Among the phytochemicals investigated, several have shown potential in preclinical and clinical studies. [21]

Curcumin, derived from turmeric, has demonstrated neuroprotective effects and the ability to reduce alpha-synuclein aggregation, a key pathological feature of PD. It exhibits anti-inflammatory properties and has shown promise in improving motor symptoms and reducing oxidative stress in animal models.

Resveratrol, found in grapes, berries, and red wine, possesses antioxidant and anti-inflammatory properties. It has shown neuroprotective effects, protecting dopamine-producing neurons and reducing neuroinflammation. Resveratrol has also exhibited potential in improving motor symptoms associated with PD. [22]

Epigallocatechin gallate (EGCG), a flavonoid abundant in green tea, has demonstrated antioxidant and anti-inflammatory effects. It exhibits neuroprotective properties, protecting dopaminergic neurons and reducing alpha-synuclein aggregation. EGCG has shown promise in improving motor function in animal models of PD. [23]

Quercetin, present in various fruits, vegetables, and grains, possesses antioxidant, anti-inflammatory, and neuroprotective properties. It has shown potential in reducing oxidative stress, preventing dopaminergic neuron loss, and improving motor symptoms in experimental models of PD.

Fisetin, found in strawberries, apples, and onions, exhibits antioxidant, anti-inflammatory, and neuroprotective effects. It has demonstrated the ability to protect dopaminergic neurons, reduce neuroinflammation, and improve motor behavior in animal models. [24,25]

While these phytochemicals have shown promise in early studies, further research is necessary to establish their safety, efficacy, and optimal dosages for PD treatment. Bioavailability and potential interactions with medications should also be carefully considered. Phytochemicals should be regarded as potential adjuncts to conventional

therapies rather than standalone treatments for PD. Individuals with PD should consult with healthcare professionals before incorporating phytochemical supplements into their treatment plan to ensure appropriate use.

Mechanism of phytochemical in targeting amyloid formation as potential therapeutic strategy

Phytochemicals found in plants, have gained attention for their potential as therapeutic agents targeting amyloid formation in neurodegenerative disorders, including Parkinson's disease (PD). Various research studies have elucidated the role of phytochemicals in this context. For instance, curcumin, a phytochemical derived from turmeric, has demonstrated the ability to inhibit the aggregation of amyloidogenic proteins, such as amyloid beta (Aβ) and alpha-synuclein, which are involved in the formation of plaques and Lewy bodies, respectively. Studies have shown that curcumin can directly interact with these proteins, impeding their aggregation and potentially reducing their neurotoxicity. [26]

Another phytochemical, resveratrol, found in grapes and berries, has been investigated for its potential in targeting amyloid formation. Resveratrol exhibits antioxidant and anti-inflammatory properties and has shown efficacy in reducing the aggregation of amyloidogenic proteins and protecting neurons in preclinical models of PD. Additionally, epigallocatechin gallate (EGCG), a phytochemical abundant in green tea, has demonstrated the ability to inhibit amyloid formation and reduce the toxicity of amyloidogenic proteins. EGCG has been reported to interfere with the aggregation process and disrupt the formation of toxic oligomers. These findings, along with research on other phytochemicals such as quercetin and fisetin, highlight the potential of phytochemicals as therapeutic strategies for targeting amyloid formation in neurodegenerative diseases. However, further studies, including clinical trials, are needed to establish their efficacy, optimal dosages, and long-term safety in human subjects. Some of the common phytochemicals with potential therapeutic activity towards Parkinson disease are found to have targeting activity on aggregation of amyloidogenic protiens. [27]

Curcumin

Curcumin has been investigated for its potential therapeutic role in targeting amyloid formation in neurodegenerative disorders such as Parkinson's disease (PD). Research has revealed several mechanisms by which curcumin may exert its effects on amyloid-related processes. Firstly, curcumin has been shown to inhibit the aggregation of amyloidogenic proteins like amyloid beta (Aβ) and alpha-synuclein, which are involved in the formation of plaques and Lewy bodies, respectively. Studies have demonstrated that curcumin can directly bind to these proteins, impeding their aggregation into toxic forms. Additionally, curcumin has been found to modulate protein misfolding and clearance pathways by upregulating the expression of heat shock proteins (HSPs) involved in protein folding and degradation. This enhancement of protective mechanisms may aid in the clearance of misfolded proteins. [28] Moreover, curcumin exhibits potent anti-inflammatory and antioxidant properties, mitigating chronic inflammation and oxidative stress, which contribute to neurodegenerative diseases. By reducing these detrimental factors, curcumin indirectly influences the production and aggregation of amyloidogenic proteins. Furthermore, curcumin has been reported to enhance the integrity of the blood-brain barrier, providing a protective barrier that regulates the

transport of molecules and prevents the infiltration of harmful substances into the brain. While curcumin's therapeutic potential has been mostly demonstrated in preclinical studies and limited clinical trials, these findings highlight its ability to target amyloid formation through multiple mechanisms, suggesting its potential as a therapeutic strategy for neurodegenerative disorders like PD.

Resveratrol

Resveratrol, a natural polyphenolic compound found in various plants, has gained significant attention for its potential therapeutic effects on amyloid formation, which is associated with several neurodegenerative diseases, including Parkinson Disease. Numerous studies have been conducted to investigate the mechanism of action of resveratrol in targeting amyloid formation and its potential as a therapeutic strategy.

One key mechanism through which resveratrol exerts its effects is by modulating the aggregation of amyloid-beta (Aβ) peptides, which are known to form plaques in the brains of Alzheimer's patients. Resveratrol has been shown to interfere with the formation and growth of Aβ aggregates, inhibiting their toxic effects. Research has demonstrated that resveratrol can directly bind to Aβ peptides, preventing their aggregation into toxic oligomers and fibrils. By inhibiting Aβ aggregation, resveratrol may help reduce the accumulation of amyloid plaques in the brain, which is a hallmark of Parkinson Disease. [29]

Furthermore, resveratrol has been found to activate certain cellular pathways involved in the clearance of amyloid deposits. It has been shown to enhance the activity of proteolytic enzymes, such as neprilysin and insulin-degrading enzyme, which are responsible for breaking down and clearing Aβ peptides from the brain. By promoting the clearance of Aβ, resveratrol may help reduce the burden of amyloid deposits and mitigate their toxic effects on neurons.

In addition to its direct effects on Aβ aggregation and clearance, resveratrol exhibits potent antioxidant and anti-inflammatory properties. Oxidative stress and neuroinflammation play crucial roles in the progression of neurodegenerative diseases, including amyloid-associated disorders. Resveratrol has been shown to scavenge reactive oxygen species and inhibit the activation of inflammatory pathways, thereby reducing oxidative stress and inflammation in the brain. These effects may contribute to the overall neuroprotective properties of resveratrol and its potential in preventing or slowing down the progression of amyloid-related diseases. [29]

Several preclinical studies have provided evidence supporting the therapeutic potential of resveratrol in various animal models of amyloid-associated diseases. These studies have demonstrated that resveratrol treatment can improve cognitive function, reduce amyloid deposition, and attenuate neuroinflammation in animal models of Parkinson Disease and other neurodegenerative disorders. However, it is important to note that the translation of these findings to human patients is still being explored, and further clinical studies are needed to establish the efficacy and safety of resveratrol as a therapeutic intervention for amyloid-related diseases.

Epigallocatechin gallate

Epigallocatechin gallate (EGCG), a major polyphenol found in green tea, has been investigated for its potential therapeutic effects on amyloid formation and its role in the treatment of amyloid-related diseases. Several research studies have examined the mechanism of action of EGCG in targeting amyloid formation and its potential as a therapeutic strategy. EGCG exerts its effects is by directly interacting with amyloidogenic proteins, such as amyloid-beta (Aβ) and tau. EGCG has been shown to bind to these proteins and inhibit their aggregation into toxic forms. By preventing the aggregation of Aβ and tau, EGCG may reduce the formation of amyloid plaques and neurofibrillary tangle. [30]

EGCG has been found to modulate various cellular pathways involved in amyloid metabolism and clearance. It has been shown to upregulate the expression and activity of proteolytic enzymes, including neprilysin and insulin-degrading enzyme, which are responsible for breaking down and clearing amyloid deposits. Additionally, EGCG has been reported to enhance the autophagy pathway, which is involved in the clearance of misfolded proteins, including amyloid aggregates. By promoting the clearance of amyloid species, EGCG may help reduce their accumulation and mitigate their toxic effects on neurons.

EGCG also possesses antioxidant and anti-inflammatory properties, which are thought to contribute to its neuroprotective effects. Oxidative stress and neuroinflammation play significant roles in the pathogenesis of amyloid-related diseases. EGCG has been shown to scavenge reactive oxygen species, inhibit lipid peroxidation, and protect against oxidative damage in neuronal cells. Moreover, it has been reported to suppress the activation of inflammatory pathways, such as nuclear factor-kappa B (NF-κB), and reduce the production of pro-inflammatory cytokines. By attenuating oxidative stress and inflammation, EGCG may help protect neurons from amyloid-induced damage. [31]

Several in vitro and animal studies have provided evidence supporting the potential therapeutic effects of EGCG in amyloid-related diseases. These studies have demonstrated that EGCG treatment can inhibit amyloid aggregation, reduce amyloid deposition, improve cognitive function, and exert neuroprotective effects in various models of Parkinson Disease and other amyloid-associated disorders. However, further research is needed to determine the optimal dosage, bioavailability, and long-term effects of EGCG in human clinical trials.

Quercetin, a flavonoid compound present in various fruits, vegetables, and grains, has been investigated for its potential therapeutic effects on amyloid formation and its role in the treatment of amyloid-related diseases, including neurodegenerative disorders. Several research studies have explored the mechanism of action of quercetin in targeting amyloid formation and its potential as a therapeutic strategy.

One of the primary mechanisms through which quercetin exerts its effects is by interfering with the aggregation of amyloidogenic proteins, such as amyloid-beta (Aβ) and alpha-synuclein. Quercetin has been shown to directly bind to these proteins and inhibit their aggregation into toxic oligomers and fibrils. By preventing the formation of amyloid aggregates, quercetin may help reduce the deposition of amyloid plaques and Lewy bodies, which are characteristic pathological features Parkinson's disease.[32]

Moreover, quercetin has been found to modulate various cellular pathways involved in amyloid metabolism and clearance. It has been shown to enhance the activity of proteolytic

enzymes, such as neprilysin and insulin-degrading enzyme, which are responsible for degrading and clearing amyloid species. Additionally, quercetin has been reported to promote autophagy, a cellular process involved in the clearance of misfolded proteins and damaged organelles. By enhancing amyloid clearance mechanisms, quercetin may help reduce the burden of amyloid deposits and alleviate their toxic effects on neurons.

Quercetin also possesses antioxidant and anti-inflammatory properties, which are believed to contribute to its potential neuroprotective effects. Oxidative stress and inflammation are key contributors to the pathogenesis of amyloid-related diseases. Quercetin has been shown to scavenge reactive oxygen species, inhibit lipid peroxidation, and protect against oxidative damage in neuronal cells. Additionally, it has been reported to suppress the activation of inflammatory pathways, such as nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs), thereby reducing the production of pro-inflammatory cytokines. By attenuating oxidative stress and inflammation, quercetin may help mitigate neuronal damage induced by amyloid species. Studies have demonstrated that quercetin treatment can inhibit amyloid aggregation, enhance amyloid clearance, improve cognitive function, and exert neuroprotective effects in models Parkinson's disease. [33]

Fisetin

Fisetin, a natural flavonoid compound found in various fruits and vegetables, has been explored for its potential health benefits, including its effects on brain function and neurodegenerative diseases. While some studies have investigated fisetin's role in reducing amyloid burden, the precise mechanisms involved are not yet well-established.

One proposed mechanism suggests that fisetin may exert its effects on amyloid formation by modulating cellular signaling pathways. It has been suggested that fisetin may inhibit the activity of enzymes involved in amyloidogenesis, such as β-secretase and γ-secretase, which play critical roles in the production of amyloid-beta (Aβ) peptides. By reducing Aβ production, fisetin may help prevent the accumulation of amyloid plaques in the brain. [34]

Additionally, fisetin possesses antioxidant and anti-inflammatory properties, which are potentially relevant in the context of amyloid-related diseases. Oxidative stress and inflammation are known to contribute to the pathogenesis of these diseases. Fisetin has been shown to scavenge free radicals, reduce oxidative damage, and inhibit inflammatory pathways, such as NF-κB and MAPKs. By mitigating oxidative stress and inflammation, fisetin may help protect against amyloid-induced neuronal damage.

Although there is a lack of specific research studies elucidating fisetin's mechanism of action in targeting amyloid formation, some preclinical studies have provided promising results regarding its potential therapeutic effects. For instance, studies using animal models of Parkinson Disease have reported that fisetin treatment can lead to improved cognitive function, reduced amyloid burden, and enhanced neuronal survival. However, it is important to note that more research, including clinical trials, is needed to fully understand fisetin's mechanisms of action, optimal dosage, and long-term effects in humans.

Conclusion

The accumulation of amyloid aggregates, such as amyloid-beta and alpha-synuclein, is a key pathological hallmark of Parkinson's disease (PD). Targeting amyloid aggregation has emerged as a potential therapeutic strategy for PD, and phytochemicals have garnered significant attention due to their diverse range of bioactive properties. This review has provided a comprehensive overview of the current research on phytochemicals as anti-amyloid agents in PD. The evidence presented in this review demonstrates the potential of various phytochemicals, including curcumin, resveratrol, EGCG, and quercetin, to modulate amyloid aggregation in PD. These phytochemicals have been shown to inhibit amyloid formation, disrupt existing aggregates, and promote amyloid clearance. Moreover, they exhibit additional neuroprotective effects, including antioxidant, anti-inflammatory, and anti-apoptotic activities, which may contribute to their therapeutic potential in PD.

Despite the promising findings, several challenges remain in the development of phytochemical-based therapies for PD. One significant hurdle is the limited bioavailability and poor pharmacokinetic properties of many phytochemicals. Strategies to enhance their stability, solubility, and delivery to the brain need to be explored to maximize their therapeutic efficacy. Furthermore, while preclinical studies have provided encouraging results, the translation of phytochemical-based therapies into clinical practice requires further investigation. Rigorous clinical trials are necessary to determine the safety, optimal dosages, and long-term effects of these compounds in PD patients.

In conclusion, this review highlights the potential of phytochemicals as promising anti-amyloid agents in PD. Their ability to modulate amyloid aggregation and exert neuroprotective effects makes them attractive candidates for the development of novel therapeutic interventions. Continued research efforts, including mechanistic studies, optimization of formulation and delivery methods, and well-designed clinical trials, are essential to advance the field and unlock the full potential of phytochemicals in the treatment of PD. Ultimately, harnessing the power of phytochemicals may offer new avenues for combating amyloid pathology and improving the lives of individuals living with PD.

References:

1. Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, et al. Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease. Curr Alzheimer Res. 2015;12:32–46.
2. Kamagata K, Tomiyama H, Hatano T, Motoi Y, Abe O, Shimoji K, et al. A preliminary diffusional kurtosis imaging study of Parkinson disease: Comparison with conventional diffusion tensor imaging. Neuroradiology. 2014;56(3):251–8.
3. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study. Lancet Neurol. 2015;14(1):57–64.
4. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 2014;383(9923):1138–46.

5. McNamara CG, Tejero-Cantero Á, Trouche S, Campo-Urriza N, Dupret D. Dopaminergic neurons promote hippocampal reactivation and spatial memory persistence. Nat Neurosci. 2014;17(12):1658–60.
6. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol 2013;70:859-866.
7. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014;29:1583-1590.
8. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-386.
9. Bach JP, Ziegler U, Deuschl G, Dodel R, Doblhammer-Reiter G. Projected numbers of people with movement disorders in the years 2030 and 2050. Mov Disord 2011;26:2286-2290.
10. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord 2013;28:311-318.
11. Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol 2013;70:1396-1402.
12. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ 3rd. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc 2012; 87:1202-1213.
13. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26(5):645–654. https://doi.org/10.1016/j.neurobiolaging.2004.06.013
14. Kummer MP, Heneka MT (2014) Truncated and modified amyloid-beta species. Alzheimers Res Ther 6(3):28–28.
15. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101–112.
16. Benilova I, Karran E, De Strooper B (2012) The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15(3):349–357.
17. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28(4):202–208.
18. Murphy MP, LeVine H (2010) Alzheimer's disease and the β-amyloid peptide. J Alzheimers Dis 19(1):311.
19. Plog BA, Nedergaard M (2018) The glymphatic system in central nervous system health and disease: past, present, and future. Annu Rev Pathol 13:379–394.
20. Hoshi A, Tsunoda A, Tada M, Nishizawa M, Ugawa Y, Kakita A (2017) Expression of aquaporin 1 and aquaporin 4 in the temporal neocortex of patients with Parkinson's disease. Brain Pathol 27(2):160–168.
21. Somani, S.J.; Modi, K.P.; Majumdar, A.S.; Sadarani, B.N. Phytochemicals and their potential usefulness in inflammatory bowel disease. Phytother. Res. 2015, 29, 339–350.

22. Kim, J.; Lee, H.J.; Lee, K.W. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J. Neurochem. 2010, 112, 1415–1430.
23. Sofi, F.; Cesari, F.; Abbate, R.; Gensini, G.F.; Casini, A. Adherence to mediterranean diet and health status: Meta-analysis. BMJ 2008, 337, a1344.
24. Nikolova, M. Screening of radical scavenging activity and polyphenol content of Bulgarian plant species. Pharmacogn. Res. 2011, 3, 256–259.
25. Martin, D.; Rojo, A.I.; Salinas, M.; Diaz, R.; Gallardo, G.; Alam, J.; De Galarreta, C.M.; Cuadrado, A. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J. Biol. Chem. 2004, 279, 8919–8929.
26. Si, H.; Liu, D. Phytochemical genistein in the regulation of vascular function: New insights. Curr. Med. Chem. 2007, 14, 2581–2589.
27. Pervin, M.; Unno, K.; Ohishi, T.; Tanabe, H.; Miyoshi, N.; Nakamura, Y. Beneficial effects of green tea catechins on neurodegenerative diseases. Molecules 2018, 23, 1297.
28. Walker, J.M.; Klakotskaia, D.; Ajit, D.; Weisman, G.A.; Wood, W.G.; Sun, G.Y.; Serfozo, P.; Simonyi, A.; Schachtman, T.R. Beneficial effects of dietary EGCG and voluntary exercise on behavior in an alzheimer's disease mouse model. J. Alzheimers Dis. 2015, 44, 561–572.
29. Chan, S.; Kantham, S.; Rao, V.M.; Palanivelu, M.K.; Pham, H.L.; Shaw, P.N.; McGeary, R.P.; Ross, B.P. Metal chelation, radical scavenging and inhibition of abeta42 fibrillation by food constituents in relation to Alzheimer's disease. Food Chem 2016, 199, 185–194.
30. Wobst, H.J.; Sharma, A.; Diamond, M.I.; Wanker, E.E.; Bieschke, J. The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett. 2015, 589, 77–83.
31. Liu, M.; Chen, F.; Sha, L.; Wang, S.; Tao, L.; Yao, L.; He, M.; Yao, Z.; Liu, H.; Zhu, Z.; et al. (-)-epigallocatechin-3-gallate ameliorates learning and memory deficits by adjusting the balance of TrkA/p75NTR signaling in APP/PS1 transgenic mice. Mol. Neurobiol. 2014, 49, 1350–1363.
32. Smith, A.; Giunta, B.; Bickford, P.C.; Fountain, M.; Tan, J.; Shytle, R.D. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int J. Pharm. 2010, 389, 207–212.
33. Choi, J.Y.; Park, C.S.; Kim, D.J.; Cho, M.H.; Jin, B.K.; Pie, J.E.; Chung, W.G. Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology 2002, 23, 367–374.
34. Koh, S.H.; Kim, S.H.; Kwon, H.; Park, Y.; Kim, K.S.; Song, C.W.; Kim, J.; Kim, M.H.; Yu, H.J.; Henkel, J.S.; et al. Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res. Mol. Brain Res. 2003, 118, 72–81.